REVIEW PAPER
The role of substance P in cancer promotion
and progression
Submission date: 2018-04-05
Final revision date: 2018-05-17
Acceptance date: 2018-06-25
Publication date: 2018-12-15
Arch Med Sci Civil Dis 2018;3(1):103-111
KEYWORDS
TOPICS
ABSTRACT
Cancer is a chronic global problem, and is the leading cause of mortality in Australia. Metastasis is a key characteristic of malignant tumors, enabling the cancer cells to move from their primary site to a secondary location. This process of translocation of cancer cells and transmigration through the blood vessels is similar to what is seen with immune cells during the inflammatory process. Substance P (SP) is known to be a significant mediator in the development and progression of inflammation, and it has been suggested that it may play a similar role in relation to metastatic tumor development via tachykinin NK1 and NK2 receptors. Therefore, the development of antagonist molecules for the NK1 receptor presents an important opportunity for exploiting these molecules as novel therapeutic agents for the treatment of cancer.
REFERENCES (99)
1.
Cotran R, Kumar V, Collins T. Robbins Pathologic Basis of Disease. Saunders, Philadelphia 6th ed. 1999; 86.
2.
DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Therap 1992; 54: 63-128.
3.
Elting LS, Avritscher EBC, Cooksley CD, Cardenas-Turanzas M, Garden AS, Chambers MS. Psychosocial and economic impact of cancer. Dent Clin North Am 2008; 52: 231-52.
4.
Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002; 70: 498-505.
7.
Bennis M, Tiret E, Matzel KE, et al. Malignant Tumours. Springer Berlin Heidelberg; Berlin, Heidelberg 2008; 193-234.
8.
de Krijger I, Mekenkamp LJM, Punt CJA, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol 2011; 224: 438-47.
12.
Bos PD, Massagué J, Nguyen DX. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
13.
Fidler IJ. Timeline: the pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8.
14.
Oppenheimer SB. Cellular basis of cancer metastasis: a review of fundamentals and new advances. Acta Histochem 2006; 108: 327-34.
15.
Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
16.
Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76: 589-605.
17.
Wang H, Lin C, Qian H. Hypotheses explaining cancer metastasis. Chin Germ J Clin Oncol 2012; 11: 689-90.
18.
Hadj AK, Malcontenti-Wilson C, Nikfarjam M, Christophi C. Lymphatic patterns of colorectal liver metastases. J Surg Res 2012; 173: 292-8.
19.
Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591-602.
21.
Porth C, Prezbindowski KS. Pathophysiology: concepts of altered health states. 7th ed. Lippincott Williams & Wilkins, London 2005.
22.
Geiger TR, Peeper DS. Metastasis mechanisms. Biochem Biophys Acta 2009; 1796: 293-308.
23.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
24.
Koop S, Schmidt EE, MacDonald IC, et al. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci USA 1996; 93: 11080-4.
25.
Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
26.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-37.
27.
Wittekind C, Neid M. Cancer invasion and metastasis. Oncology 2005; 69 Suppl 1: 14-6.
30.
Payan DG. Neuropeptides and inflammation: the role of substance P. Ann Rev Med 1989; 40: 341-52.
31.
Fridman R. Matrix metalloproteinases. Biochim Biophys Acta Mol Cell Res 2010; 1803: 1-2.
32.
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
34.
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
35.
Gupta SP. Matrix Metalloproteinase Inhibitors: Specificity of Binding and Structure-Activity Relationships. Springer-Verlag 2012.
36.
Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004; 287: G315-9.
37.
Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8: 3267-73.
38.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
39.
Researchers from National Institutes of Health report on findings in inflammation. Clin Oncol Week 2010: 997.
40.
Achyut BR, Bader DA, Robles AI, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-[beta] signaling. PLoS Genet 2013; 9: e1003251.
41.
Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology: analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8: 711-9.
42.
von Hertzen LC, Joensuu H, Haahtela T. Microbial deprivation, inflammation and cancer. Cancer Metastasis Rev 2011; 30: 211-23.
43.
Salas A. The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease? Gut 2013; 62: 1392-3.
44.
Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-80.
45.
Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-58.
46.
Li X, Ma G, Ma Q, et al. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol Cancer Res 2013; 11: 294-302.
47.
Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B. The significance of substance P in physiological and malignant haematopoiesis. J Clin Pathol 2007; 60: 749-55.
48.
Spitsin S, Meshki J, Winters A, Tuluc F, Benton TD, Douglas SD. Substance P-mediated chemokine production promotes monocyte migration. J Leukoc Biol 2017; 101: 967-73.
49.
Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009; 30: 271-6.
50.
Researchers from University of Pennsylvania Detail Findings in Cytokines (Substance P-mediated chemokine production promotes monocyte migration). NewsRX LLC 2017; 193.
51.
Porter R, O’Connor M. Substance P in the nervous system. London; Summit, N.J., USA Pitman 1982.
52.
Desai MC. Overview: central and peripheral nervous system: recent advances in the discovery and characterization of substance P antagonists. Exp Opin Therap Patents 1994; 4: 315-21.
53.
Cador M, Rivet JM, Kelley AE, Le Moal M, Stinus L. Substance P, neurotensin and enkephalin injections into the ventral tegmental area: comparative study on dopamine turnover in several forebrain structures. Brain Res 1989; 486: 357-63.
54.
Ortiz-Prieto A, Bernabeu-Wittel J, Zulueta-Dorado T, Lorente-Lavirgen AI, Muñoz M. Immunolocalization of substance P and NK-1 receptor in vascular anomalies. Arch Dermatol Res 2017; 309: 97-102.
55.
Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Investig New Drugs 2010; 28: 187-93.
56.
Pernow B. Distribution of substance P in the central and peripheral nervous system. Nature 1953; 171: 746.
57.
Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761-7.
58.
Blum AM, Elliott DE, Metwali A, Li J, Qadir K, Weinstock JV. Substance P regulates somatostatin expression in inflammation. J Immunol 1998; 161: 6316-22.
59.
Ringel Y, Carroll IM, Palsson OS, Sartor RB. S1249 substance P and its mucosal receptors – possible mediators of inflammation and noxious sensation in irritable bowel syndrome. Gastroenterology 2009; 136: A221-2.
60.
D’Souza M, Garza MA, Xie M, Weinstock J, Xiang Q, Robinson P. Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by taenia crassiceps infection. J Parasitol 2007; 93: 1121-7.
61.
Bhatia M. Hydrogen sulfide and substance P in inflammation. Antioxid Redox Signal 2010; 12: 1191-202.
62.
Killough SA, Lundy FT, Irwin CR. Substance P expression by human dental pulp fibroblasts: a potential role in neurogenic inflammation. J Endodont 2009; 35: 73-7.
63.
Luber-Narod J, Austin-Ritchie T, Hollins RC, et al. Role of substance P in several models of bladder inflammation. Urol Res 1997; 25: 395-9.
64.
Corrigan F, Vink R, Turner RJ. Inflammation in acute CNS injury: a focus on the role of substance P: neurogenic inflammation in acute CNS injury. Br J Pharmacol 2016; 173: 703-15.
65.
Averbeck B, Reeh PW. Interactions of inflammatory mediators stimulating release of calcitonin gene-related peptide, substance P and prostaglandin E 2 from isolated rat skin. Neuropharmacology 2001; 40: 416-23.
66.
Mascetta G, di Mola FF, Tavano F, et al. Substance P and neprilysin in chronic pancreatitis. Eur Surg Res 2012; 48: 131-8.
67.
O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167-80.
68.
Khan MM, Douglas SD, Benton TD. Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor. J Neuroimmunol 2012; 242: 1-8.
69.
Rodriguez-Grande B, Blackabey V, Gittens B, Pinteaux E, Denes A. Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behavior Immun 2013; 29: 51-61.
70.
Lieb K, Schaller H, Bauer J, Berger M, Schulze-Osthoff K, Fiebich BL. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. J Neurochem 1998; 70: 1577-83.
71.
Saban MR, Saban R, Bjorling D, Haak-Frendscho M. Involvement of leukotrienes, TNF-alpha, and the LFA-1/ICAM-1 interaction in substance P-induced granulocyte infiltration. J Leukoc Biol 1997; 61: 445-51.
72.
Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150: 4478-85.
73.
Li J, Mahiouz DL, Farthing PM, Haskard DO, Thornhill MH. Heterogeneity of ICAM-1 expression, and cytokine regulation of ICAM-1 expression, in skin and oral keratinocytes. J Oral Pathol Med 1996; 25: 112-8.
74.
Matis WL, Lavker RM, Murphy GF. Substance P induces the expression of an endothelial-leukocyte adhesion molecule by microvascular endothelium. J Investig Dermatol 1990; 94: 492-5.
75.
Kabashima H, Nagata K, Maeda K, Iijima T. Involvement of substance P, mast cells, TNF-alpha and ICAM-1 in the infiltration of inflammatory cells in human periapical granulomas. J Oral Pathol Med 2002; 31: 175-80.
76.
Halliday DA, McNeil JD, Betts WH, Scicchitano R. A role for the C-terminal fragment of substance P, SP 7-11 in the pathogenesis of arthritis. Regulatory Peptides 1993; 46: 195-7.
77.
Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann NY Acad Sci 2011; 1217: 83-95.
78.
Pascual DW. The role of tachykinins on bacterial infections. Front Biosci 2004; 9: 3209-17.
79.
Susmit S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol 2017; 199: 1543-52.
80.
Varon C, Megraud F. Helicobacter pylori infection and gastric cancer. Revue Francophone des Laboratoires 2013; 2013: 67.
81.
Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31: 152-61.
82.
Tokuda M. Substance P activates p38 mitogen-activated protein kinase to promote IL-6 induction in human dental pulp fibroblasts. Connect Tissue Res 2005; 46: 153-8.
83.
Yang CM, Hsiao LD, Chien CS, Lin CC, Luo SF, Wang CC. Substance P-induced activation of p42/44 mitogen-activated protein kinase associated with cell proliferation in human tracheal smooth muscle cells. Cell Signal 2002; 14: 913-23.
84.
Muñoz M, Rosso M, Coveñas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 2010; 17: 504-16.
85.
Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Investig 2003; 83: 731-42.
86.
Muñoz M, González-Ortega A, Coveñas R. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Investig New Drugs 2012; 30: 529-40.
87.
Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 2013; 48: 1-9.
88.
Erin N, Duymuş O, Oztürk S, Demir N. Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis. Regul Pept 2012; 179: 101-8.
89.
Szotek PP, Donahoe PK, Pieretti-Vanmarcke R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-9.
90.
Kohara H, Tajima S, Yamamoto M, Tabata Y. Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 2010; 31: 8617-25.
91.
Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Investig 1994; 94: 2036-44.
92.
Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN. Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion. Clin Exp Metastasis 2013; 30: 1-12.
93.
Garcia-Recio S, Gascón P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int 2015; 2015: 495704.
94.
Vilisaar J, Kawabe K, Braitch M, et al. Reciprocal regulation of substance P and IL-12/IL-23 and the associated cytokines, IFNgamma/IL-17: a perspective on the relevance of this interaction to multiple sclerosis. J Neuroimmune Pharmacol 2015; 10: 457-67.
95.
Dickerson C, Undem B, Bullock B, Winchurch RA. Neuropeptide regulation of proinflammatory cytokine responses. J Leukoc Biol 1998; 63: 602-5.
96.
Nakamura M, Chikama T, Nishida T. Up-regulation of integrin alpha 5 expression by combination of substance P and insulin-like growth factor-1 in rabbit corneal epithelial cells. Biochem Biophys Res Commun 1998; 246: 777-82.
97.
Muñoz M, González-Ortega A, Rosso M, et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 2012; 38: 318-25.
98.
Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig New Drugs 2008; 26: 111-8.
99.
Muñoz M, Rosso M, González-Ortega A, Coveñas R. The NK-1 receptor antagonist L-732,138 induces apoptosis and counteracts substance P-related mitogenesis in human melanoma cell lines. Cancers 2010; 2: 611-23.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
